Lysophosphatidic acid (LPA) and sphingosine 1-phosphate (S1P) are two representative lysophospholipid mediators acting on G-protein-coupled receptors (GPCRs). LPA was first identified three decades ago as a factor affecting blood pressure, platelet aggregation, and smooth muscle contraction [1] [2] [3] [4] [5] and rediscovered as a mitogenic serum lipid inducer of neurite retraction [6, 7] . The name 'lyso' originates from lysis of blood cells; thus, the non-specific detergent action of LPA has been doubted. In 1996, the high potency (nmol/L range) and GPCR implications of LPA were finally connected to the discovery of the first LPA receptor (LPA 1 , formerly known as Edg-2) [8] . Subsequently, LPA 2 and LPA 3 were identified as members of the endothelial differentiation gene (Edg) subfamily of GPCRs [9] [10] [11] . These three LPA receptors (Edg family) share a high homology with each other [12] . Recently, the non-Edg family of LPA receptors, LPA 4 (GPR23, p2y9), LPA 5 (GPR92), and LPA 6 (p2y5), were reported as members of the purinergic GPCR cluster [13] [14] [15] [16] [17] [18] [19] . Using the GPCR-Gα 16 fusion expression system, Fujita's group reported GPR87 as another LPA receptor and P2Y 10 as a dual receptor for both LPA and S1P [20, 21] . These results have not yet been confirmed by other research groups [22] . Instead, lysophosphatidylserine has been suggested to act as a ligand for P2Y 10 without confirmation of LPA and S1P as ligands in NIH3T3 cells [23] . S1P was initially reported 15 years ago to be a second messenger, mediating an increase in calcium levels due to PDGF and IgE signaling [24, 25] . The molecular target of S1P in the cytosol has not yet been identified. The initial finding of an S1P-induced calcium increase stimulated research in S1P biology and was linked to its recognition as an intercellular first messenger. The involvement of trimeric G proteins in S1P-induced actions as well as pertussis toxin sensitivity strongly suggested the presence of S1P GPCRs in the plasma membrane [26] [27] [28] [29] [30] . The discovery of S1P 1 (formerly known as Edg-1) in 1998, along with four other receptors (S1P 2-5 ) of the Edg subfamily GPCRs, became a milestone in S1P biology [12, [31] [32] [33] [34] [35] [36] .
Discovery of GPCRs for LPA and S1P
Lysophosphatidic acid (LPA) and sphingosine 1-phosphate (S1P) are two representative lysophospholipid mediators acting on G-protein-coupled receptors (GPCRs). LPA was first identified three decades ago as a factor affecting blood pressure, platelet aggregation, and smooth muscle contraction [1] [2] [3] [4] [5] and rediscovered as a mitogenic serum lipid inducer of neurite retraction [6, 7] . The name 'lyso' originates from lysis of blood cells; thus, the non-specific detergent action of LPA has been doubted. In 1996, the high potency (nmol/L range) and GPCR implications of LPA were finally connected to the discovery of the first LPA receptor (LPA 1 , formerly known as Edg-2) [8] . Subsequently, LPA 2 and LPA 3 were identified as members of the endothelial differentiation gene (Edg) subfamily of GPCRs [9] [10] [11] . These three LPA receptors (Edg family) share a high homology with each other [12] . Recently, the non-Edg family of LPA receptors, LPA 4 (GPR23, p2y9), LPA 5 (GPR92), and LPA 6 (p2y5), were reported as members of the purinergic GPCR cluster [13] [14] [15] [16] [17] [18] [19] . Using the GPCR-Gα 16 fusion expression system, Fujita's group reported GPR87 as another LPA receptor and P2Y 10 as a dual receptor for both LPA and S1P [20, 21] . These results have not yet been confirmed by other research groups [22] . Instead, lysophosphatidylserine has been suggested to act as a ligand for P2Y 10 without confirmation of LPA and S1P as ligands in NIH3T3 cells [23] . S1P was initially reported 15 years ago to be a second messenger, mediating an increase in calcium levels due to PDGF and IgE signaling [24, 25] . The molecular target of S1P in the cytosol has not yet been identified. The initial finding of an S1P-induced calcium increase stimulated research in S1P biology and was linked to its recognition as an intercellular first messenger. The involvement of trimeric G proteins in S1P-induced actions as well as pertussis toxin sensitivity strongly suggested the presence of S1P GPCRs in the plasma membrane [26] [27] [28] [29] [30] . The discovery of S1P 1 (formerly known as Edg-1) in 1998, along with four other receptors (S1P [2] [3] [4] [5] ) of the Edg subfamily GPCRs, became a milestone in S1P biology [12, [31] [32] [33] [34] [35] [36] .
Development of agonists and antagonists for LPA receptors
Prior to receptor cloning, various aspects of LPA receptor Pharmacological tools for lysophospholipid GPCRs: development of agonists and antagonists for LPA and S1P receptors Dong-Soon IM * structure-activity relationships had been studied: 1) fatty acid chain length and the presence of double bonds, 2) acyl and alkyl linkage, 3) stereo-selectivity on the sn-2 position, and 4) modification of phosphate groups [37] . Oleoyl LPA (18:1) was considered the optimum ratio to increase Ca 2+ levels in A431 cells [38] . Alkyl LPA showed a better effect than acyl LPA in platelet aggregation assays and an equal effect in other responses [39, 40] . Several groups reported a lack of stereo-selectivity on the sn-2 position of LPA. Early studies showed that modification of the phosphate group resulted in an absence of LPA responses [38, 40] . The initial synthetic approach to LPA response was characterized using platelet aggregation assays. Replacement of the glycerol backbone with amino acids resulted in the production of N-palmitoyl serine phosphatidic acid (NPSPA) and N-palmitoyl tyrosine phosphatidic acid (NPTyrPA) [40] . These molecules were not active on platelet aggregation in humans, but did demonstrate activity as LPA receptor antagonists in Xenopus [41] . Later, NPSPA and NPTyrPA were reported as partial agonists of mammalian LPA receptors [42, 43] . Sugiura et al introduced the ethanolamine-based LPA mimetic, N-acyl aminoethanol phosphoric acid (NAEPA), as an equipotent agonist of platelet aggregation [40] . Later, research groups from the University of Virginia used NASPA and NAEPA as platforms to synthesize a series of VPC compounds [37, 44] . The phosphonate analogue of NAEPA lost its platelet aggregation properties [40] , but methylene phosphonate LPA was equipotent to LPA as an inhibitor of forskolin-driven cAMP accumulation in rat C6 glioma cells [45] . Jalink et al synthesized various phosphonate analogues along with fatty alcohol phosphates and the methyl ester of LPA (lysophosphatidylmethanol, LPM), but could not show a significant impact of these compounds on Ca 2+ increase in A431 cells [38] . Ironically, these chemicals turned out to be selective or non-selective agonists of cloned LPA receptors (see details below). In the early era of LPA biology, suramin and lysophosphatidylglycerol were used to demonstrate GPCR involvement in LPA responses [46] and as an antagonist of LPA-induced Ca 2+ responses in Jurkat T cells [47] , respectively.
LPA GPCR agonists
Since the discovery of the three-Edg family of LPA receptors, the development of selective receptor-subtype agonists and antagonists has accelerated. The optimal chain length and the presence of double bonds have been found to vary depending on receptor subtype. For example, LPA 3 showed a preference for unsaturated LPA similar to oleoyl LPA [48] , whereas LPA 6 showed a preference for 2-acyl LPA [19] . Synthesis of LPA derivatives with phosphonate or thiophosphate groups instead of the phosphate group showed receptor-subtype selective activity similar to 1-oleoyl-2-O-methyl-rac-glycerophosphothionate (OMPT), 1-O-acyl-α-fluoromethylenephosphonate, and α-hydroxymethylenephosphonate LPA analogues as LPA 3 receptor selective agonists [49] [50] [51] [52] . The phosphonate derivatives also provided a path toward the development of phosphataseresistant long-lasting LPA derivatives [53] . A dialkyl phosphatidic acid (PA) 8:0 analog with a thiophosphate was reported as a potent and selective LPA 3 agonist [54] , but later, agonistic activity on the LPA 5 receptor and antagonistic activity on the LPA 1,3 receptors was reported [55] . Based on computational modeling, dodecyl fatty alcohol phosphate was shown to be a specific LPA 2 receptor agonist [56] , and later, oleoyl-thiophosphate was identified as a pan-agonist (LPA 1-3 ) [43] . A methylene phosphonate LPA analogue was reported as a selective LPA 2 agonist, but it recently was shown to exert agonistic and antagonistic activities on LPA 5 and LPA 3 , respectively [52, 57] . T-15 (LPA 1 agonist) and T-13 (LPA 3 agonist) were both synthesized using a carbohydrate scaffold [58] . Darmstoff analogues were introduced as novel scaffolds for subtype-selective LPA receptor ligands [59] . Finally, octadecenyl phosphate was shown to be a selective agonist for LPA 4 and LPA 5 receptors [55] . Although alkyl LPA has been shown to exert equipotent activity on each Edg-family LPA receptor compared to acyl LPA [60] , alkyl LPA was found to be more potent than acyl LPA in platelet aggregation responses [3] . Therefore, the Edgfamily LPA receptors were not able to account for the LPA response in platelets [61] . Recently, non-Edg (purinergic) LPA receptors have been identified. The LPA 5 /GPR92 receptor has demonstrated alkyl preference and a presence in platelets [55] . Farnesyl diphosphate, N-arachidonyl glycine, and carba-cyclic phosphatidic acid were shown to be selective agonists for LPA 5 [55, 62, 63] . LPA 6 /p2y5 showed a preference for 2-acyl LPA over 1-acyl LPA [19] . Alkyl-OMPT, an LPA 3 agonist, and 2-linoleoyl LPA showed better agonistic effects on the LPA 6 receptor than 2-oleoyl LPA showed [19, 64] . In contrast, the methyl ester of LPA (LPM) was shown to be a pan-agonist for LPA [1] [2] [3] [4] [5] although it was less potent than LPA [65] .
LPA GPCR antagonists
The development of LPA derivatives with a bulky group on the sn-2 position has demonstrated the stereo-selectivity of LPA receptors and has led to the further development of the LPA 1 /LPA 3 selective antagonists VPC12249 and VPC32183 [66, 67] . 2-Pyridyl-containing phosphonate was developed as a non-hydrolyzable LPA 3 receptor antagonist [68] . Dioctylglyceropyrophosphate (DGPP) and Ki16425 were determined to be selective LPA 1 /LPA 3 antagonists following screening of available lipid and non-lipid molecules [69, 70] . The thiophosphate version of PA 8:0 was shown to be the most potent LPA 3 antagonist, whereas the dialkyl PA 8:0 analog with a thiophosphate was shown to be a potent and selective LPA 3,5 agonist, as mentioned above [54, 55] . Tetradecyl-phosphonate was identified as a pan-antagonist (LPA 1-3 ) [43] . Furthermore, farnesyl phosphate and farnesyl diphosphate potently and selectively blocked the LPA 3 -mediated Ca 2+ increase [71] , although farnesyl diphosphate is a LPA 5 selective agonist, as mentioned above [55] . T-14, which used a carbohydrate scaffold, was shown to be an LPA 3 antagonist [58] . Recently, virtual screening identified non-lipid LPA 3 antagonist NSC161613, LPA 2 antagonist H2L5186303, LPA 4,5 antagonist 5987411, and LPA 1, 6 antagonist 5765834 [55, 72] . An LPA analogue of α-bromomethylene phosphonate was reported to act 1215 www.chinaphar.com Im DS Acta Pharmacologica Sinica npg as a pan-antagonist to LPA [1] [2] [3] [4] and an autotoxin inhibitor [52, 73] .
Pharmacological tools for LPA GPCR signaling Commercially available chemicals for studying LPA receptor subtypes are currently in development, although the effects of previously developed chemicals on recently identified nonEdg LPA receptors have not been completely verified ( Figure  1 ). For LPA 1 
Development of agonist and antagonist for S1P receptors
In contrast to LPA, the structure-activity relationship of S1P has a very short history. Using cloned S1P receptors, sphinganine-1-phosphate (dihydro-S1P) and sphingosylphosphorylcholine (SPC) were shown to be equipotent and far less potent on each S1P receptor [36, [74] [75] [76] .
S1P GPCR agonists
Following the cloning of the S1P receptors, the development of S1P agonists and antagonists began. The importance of the D-erythro configuration of S1P was demonstrated using the cloned receptors [77] . The linkage of the immune modulator FTY720 to S1P receptors, however, boosted this area of research and opened a new direction for S1P biology [78] [79] [80] . Lymphopenia induction by inhibiting lymphocyte egress from lymphoid organs was shown to be mediated through the S1P 1 receptor [81] . High-throughput screening (HTS) of an available chemical library showed that SEW2871 acted as an in vivo active heterocyclic S1P 1 selective agonist [81, 82] and compound 26 was synthesized as a potent 3,5-diphenyl-12,4-oxadiazole S1P 1 agonist [83] . Later, using ultra-HTS, 3,5-diaryloxadiaxole (CYM5181) and dicyclohexylamide were found to be selective agonists for S1P 1 and S1P 3 , respectively [84] . Using computational modeling, CYM-5442 was developed as an S1P 1 selective agonist that was more potent than CYM5181 [85] . AUY954, an aminocarboxylate analogue of FTY720, was also introduced as an S1P 1 selective agonist [86] . VPC01091, a cyclized analogue of FTY720, was shown to act as an orally active S1P 1 agonist and an S1P 3 antagonist [87] . KRP-203 is a pro-drug immune modulator similar to FTY720; the phosphorylated form of KRP-203 was shown to be a selective S1P 1 agonist [88, 89] . Constrained azacyclic analogues of FTY720 showed selective agonist activities on S1P 4 and S1P 5 receptors [90] . Finally, phytosphingosine-1-phosphate was shown to act as a potent and selective agonist on the S1P 4 receptor [76] .
S1P GPCR antagonists
Suramin was temporarily used as an S1P 3 antagonist [75, 91] . Human S1P 5 was also reported to be sensitive to suramin and its analogue NF023 [92] . Following screening of an available chemical library, JTE-013, a pyrazopyridine derivative, was identified as an S1P 2 antagonist [93, 94] . Modification of the FTY720-phosphate structure led to the development of VPC23019 and VPC25239 as selective S1P 1 /S1P 3 antagonists [95] . As mentioned above, VPC01091 is an orally active S1P 1 agonist and S1P 3 antagonist [87] . W146, hexyl phenyl amide phosphonate, was found to Ki16425 [70] Antagonist Antagonist Antagonist (250 nmol/L) (5600 nmol/L) (360 nmol/L) DGPP [69] Antagonist Antagonis (6600 nmol/L) (106 nmol/L) VPC32183 [67] Antagonist Antagonist (109 nmol/L) (175 nmol/L) VPC12249 [66] Antagonist Antagonist (137 nmol/L) (428 nmol/L) 2-Pyridyl phosphonate [68] Antagonist Thiophosphatidic acid 8:0 [54] Antagonist Antagonist (360 nmol/L) (5 nmol/L) T14 [58] Antagonist NSC161613 [72] Antagonist (24 nmol/L) Compound 12 [120] Antagonist Antagonist (48 nmol/L) (230 nmol/L) H2L5186303 [72] Antagonist Antagonist (7.2 nmol/L) (310 nmol/L) 5987411 [55] Antagonist Antagonist (741 nmol/L) (1300 nmol/L) 5765834 [55] Antagonist Antagonist (48 nmol/L) (292 nmol/L) α-bromomethylene Antagonist Antagonist Antagonist Antagonist Weak agonist phosphonate [52, 55, 73, 117] (751 nmol/L) (304 nmol/L) (380 nmol/L) (167 nmol/L) Tetradecyl-phosphonate [43] Antagonist Antagonist Antagonist (10000 nmol/L) (5500 nmol/L) (3100 nmol/L) Farnesyl diphosphate [55, 71] Antagonist Antagonist Antagonist Agonist (2100 nmol/L) (155 nmol/L, (1980 nmol/L) (40 nmol/L) 4600 nmol/L) Carba cyclic PA [55] Agonist OMPT [49] Agonist (68 nmol/L) Alkyl OMPT [19, 64] Agonist Agonist Agonist (790 nmol/L) (62 nmol/L) α-fluoromethylene Weak agonist Weak agonist Agonist phosphonate [51] (0.5 nmol/L) α-hydroxymethyleneAgonist phosphonate [52] (393 nmol/L) Compound 8bo [121] Agonist Agonist (9.1 nmol/L) (123 nmol/L) Dialkyl thiophosphatidic Agonist Agonist Agonist Agonist acid 8:0 [54, 55] (695 nmol/L) (5720 nmol/L) (3 nmol/L) Antagonist Antagonist (382 nmol/L) (184 nmol/L) Dodecylphosphate [56] Agonist Antagonist (700 nmol/L) (90 nmol/L) α-methylene Agonist Weak agonist Agonist phosphonate [52, 55] (>281 nmol/L) (3900 nmol/L) Antagonist (1420 nmol/L) T15 [58] Agonist
www.chinaphar.com Im DS Acta Pharmacologica Sinica npg be a selective S1P 1 antagonist [96] . VPC44116, an octyl analogue of W146 and γ-aminophosphonate analogue of VPC23019, antagonized lymphopenia and lung permeability via the S1P 1 receptor [97] . SB64146 was reported to act as an inverse agonist on the S1P 1 receptor [98] . Ascotricins A and B were isolated from a cultured broth of a fungus identified as Ascotricha chartarum and shown to inhibit the S1P 1 receptor and S1P-mediated HUVEC migration [99] . Sankyo Co synthesized compound lead 2 (CL2), 2-(4-ethoxyphenoxy)-5-(3-octadecyl-5-oxo-4,5-dihydro-1H-pyrazol-1-yl) benzenesulfonate, which antagonized the S1P 1 >S1P 3 >S1P 2 receptors [100] . Human S1P 1 receptor-selective antagonist and agonist effects of a rat monoclonal antibody (4B5.2) in vivo were also reported [101] . Using a 3D database search, BML-241, 2-alkylthiazolidine-4-carboxylic acid, was found to act as an S1P 3 antagonist, but its selectivity and potency were not recapitulated in CHO-K1 cells expressing the S1P 3 receptor [102, 103] . A pharmacophore-based design of an S1P 3 antagonist with a 3,4-dialkyoxybenzophenone scaffold was suggested [104] .
Pharmacological tools for S1P GPCR signaling Commercially available tools for studying S1P receptor subtypes are highlighted in Figure 2 . For S1P 1 receptor signaling, CYM-5442 or SEW2871, both potent selective S1P 1 agonists, and W146, a selective S1P 1 antagonist, should be sufficient to elucidate S1P 1 receptor involvement. S1P 2 receptor signaling could be dissected using JTE-013, an S1P 2 selective antagonist. For S1P 3 GPCR signaling, a combined application of an S1P 1,3 antagonist (VPC23019) and S1P 1 antagonist (W146) or S1P 1 agonist (CYM-5442) could be useful. Phytosphingosine 1-phosphate, an S1P 4 selective agonist, could be used to study S1P 4 -mediated signaling. S1P 1,3 antagonist (VPC23019)-insensitive, S1P 2 antagonist (JTE-013)-insensitive, S1P 4 agonist-nonresponsive, and S1P-or FTY720-phosphate-sensitive signaling might be interpreted as S1P 5 receptor or unidentified S1P receptor signaling ( Table 2) .
Development of drugs acting on lysophospholipid GPCRs
Prior to the molecular cloning of GPCRs for LPA and S1P, a number of studies were conducted with the primary goal of determining the functions of lipid mediators at both the cellular and the organ level. These functions included platelet aggregation, smooth muscle contraction, and cell proliferation, among others [1] [2] [3] [4] [5] [6] 105] . The discovery of GPCRs allowed signal T13 [58] Week agonist Agonist (500 nmol/L) (0.5 nmol/L) Octadecenyl phosphate [55] Agonist Agonist (608 nmol/L) NPSPA [11, 43, 122] Weak agonist Weak agonist Weak agonist (1850 nmol/L) (1600 nmol/L) NPTyrPA [43, 55, 122] 
Antagonist
Weak agonist Antagonist Agonist (3450 nmol/L) (11000 nmol/L) (5570 nmol/L) NAEPA [11] Agonist Agonist Weak agonist Oleoyl-thiophosphate [43] Agonist Agonist Agonist (193 nmol/L) (244 nmol/L) (546 nmol/L) LPM [65] Agonist Agonist Agonist Agonist Agonist 1218 www.nature.com/aps Im DS Acta Pharmacologica Sinica npg transduction studies to proceed in cells over-expressing the receptors and in receptor knock-down transgenic mouse models [106] [107] [108] [109] . The discovery of the pathophysiological significance of LPA and S1P, particularly on each receptor subtype, would contribute favorably to new drug development. In developing new medications acting on LPA or S1P receptors, subtype selectivity would be a major issue along with potency and efficacy to avoid side effects and ensure drug safety. FTY720 was initially developed as an immune modulator for organ transplant patients [110] . At present, this compound is under clinical study for the treatment of multiple sclerosis [111] . Amira Pharmaceuticals reported LPA 1 selective antagonist (4'-{4-[(R)-1-(2-chloro-phenyl)-ethoxycarbonylamino]-3-methyl-isoxazol-5-yl}-biphnyl-4-yl)-acetic acid, AP2966, which showed good therapeutic potential in idiopathic pulmonary fibrosis and good pharmacokinetic profiles, including oral bioavailability [112] . Pfizer global research and development introduced the S1P 1 selective agonists PF-A and PF-B. These agonists resulted in lymphopenia in rats and monkeys similar to FTY720 and reduced collagen-induced arthritis [113] . Using a different approach, Lpath Inc. recently introduced monoclonal antibodies against S1P and LPA. Humanized anti-S1P monoclonal antibody (mAb) sonepcizumab blocked the tumorigenic effect of S1P produced by cancer cells as well as the angiogenic effect induced during pathological angiogenesis [114, 115] . The LPA receptor pan-antagonist (LPA [1] [2] [3] [4] and autotoxin inhibitor, α-bromomethylene phosphonate LPA analogue, was shown to be an excellent anti-cancer agent [116, 117] .
Closing remarks
Following the initial discoveries of LPA activity 30 years ago and S1P activity 15 years ago, a dark dawn era in lysophospholipid biology occurred due to the lack of identifiable targets. The discovery of the Edg-family GPCRs for LPA and S1P shined light on this field. The first meeting that focused on lysophospholipid biology was a New York Academy of Science meeting conducted in 1999 at Rockefeller University [118] . Since 2001, FASEB summer research conferences on lysophospholipids have been held biannually. Lysophospholipid receptor nomenclature has been systematically assigned [119] , and more LPA receptors (purinergic or non-Edg LPA recep- [85] Agonist (1.2 nmol/L) CYM-5181 [84] Agonist (3.4 nmol/L) SEW2871 [81] Agonist (13 nmol/L) Compound 26 [83] Agonist (0.6 nmol/L) Agonist (12000 nmol/L) Agonist (70 nmol/L) Agonist (1.0 nmol/L) Compound 12 [90] Agonist (7.4 nmol/L) Agonist (10.2 nmol/L) Compound 18 [90] Agonist (16.8 nmol/L) Agonist (5.8 nmol/L) VPC44116 [97] Antagonist (30 nmol/L) Antagonist (300 nmol/L) Partial agonist (33 nmol/L) W146 [96, 106] Antagonist (36 nmol/L) SB649146 [98] Antagonist (300 nmol/L) VPC23019 [95] Antagonist (13.8 nmol/L) Antagonist (1175 nmol/L) Agonist (263 nmol/L) Partial agonist (85.1 nmol/L) VPC25239 [95] Antagonist (13.4 nmol/L) Antagonist (97.7 nmol/L) Agonist (166 nmol/L) Partial agonist (11.5 nmol/L) CL2 [100] Antagonist (4400 nmol/L) Antagonist (37000 nmol/L) Antagonist (6700 nmol/L) VPC01091-P [87] Agonist (6.6 nmol/L) Antagonist Agonist Partial agonist Ascotricins Antagonist (8200 nmol/L, A and B [99] 1800 nmol/L) JTE-013 [93] Antagonist (17 nmol/L) BML-241 [102, 103] Antagonist (?) TY-52156 [123] Antagonist (110 nmol/L) DS-SG-44 [124] Agonist Agonist Agonist KRP-203-P [88, 89] Agonist (0.8 nmol/L) Agonist (9.6 nmol/L) PhytoS1P [76] Agonist (1.6 nmol/L) DihydroS1P [36, 75, 76] Agonist Agonist Agonist Agonist (8.6 nmol/L) Agonist SPC [34, 36, 75] Partial agonist Partial agonist Partial agonist Partial agonist Partial agonist FTY720-P [78, 79] Agonist ( Acta Pharmacologica Sinica npg tors) are being discovered each year. Every two years, we have had exciting findings including the linkage of FTY720 to the S1P receptor, discovery of an autotoxin as a LPA-producing lysoPLD, lysolipid-sensitive proton-sensing GPCRs (OGR1 subfamily), and finally, the development of new chemicals. This review integrates accumulated information regarding pharmacological tools for lysophospholipid GPCR signaling to compare their characteristics and provides valuable information such as available chemical sources. Using a combination of receptor expression patterns in each organ or cell, these pharmacological tools might prove useful in defining the pathophysiological impact and significance of lysophospholipids. As mentioned above, the control of lysophopholipid functions using specific agonists or antagonists will contribute toward novel drug development. At a 2009 FASEB meeting in Carefree (Arizona, USA), we began to see several of the chemicals described here, in addition to FTY720, being used in clinical applications [112] [113] [114] 116] . We now know more about many things than ever before. It is very likely that in the near future, the agonists/antagonists for LPA or S1P receptors will be on the market commercially and that there will be a section on lysophospholipid GPCRs in every basic pharmacology textbook.
